964 F.3d 1049
Fed. Cir.2020Background
- Patents-in-suit (U.S. Pat. Nos. 8,063,182 and 8,163,522) claim the fusion protein etanercept (p75 TNF receptor extracellular domain fused to IgG1 hinge-CH2-CH3) and methods of making it; Sandoz filed an aBLA to market a biosimilar (Erelzi).
- Sandoz stipulated to infringement; trial focused solely on validity (obviousness-type double patenting, written description, and obviousness). The district court found the asserted claims not invalid and entered judgment for Immunex/Roche.
- Key licensing history: Roche filed the priority applications; Immunex later obtained an exclusive, paid-up license under a 2004 Accord & Satisfaction giving Immunex prosecution control, first right to sue, sublicensing rights, and an option to obtain an assignment of the patents for $50,000; Roche retained a secondary right to sue and limited retained rights (research use, veto over some assignments).
- On appeal Sandoz challenged validity on three grounds and argued Immunex effectively owned the patents (so common-ownership ODP applies) because the Accord transferred “all substantial rights.”
- The Federal Circuit held (majority): the “all substantial rights” test may be informative for determining common ownership in ODP cases where prosecution control is transferred, but under the totality of the 2004 Accord Roche did not transfer all substantial rights to Immunex (Roche retained meaningful enforcement and alienation rights); therefore ODP did not apply. The court also affirmed the district court’s written-description and obviousness rulings.
- Judge Reyna dissented on common-ownership/ODP grounds, reasoning the retained rights were illusory and that the one-way ODP test should have applied, rendering the patents invalid.
Issues
| Issue | Plaintiff's Argument (Immunex/Roche) | Defendant's Argument (Sandoz) | Held |
|---|---|---|---|
| Obviousness-type double patenting (ODP): are the patents "commonly owned" such that ODP applies? | Accord is a license and Roche retained key rights (secondary right to sue, veto over assignments); Accord did not transfer all substantial rights so patents are not commonly owned. | Accord transferred all substantial rights (prosecution control, exclusivity, first right to sue, paid-up license) to Immunex; Immunex is the effective patentee and ODP should apply. | The court: the "all substantial rights" test can inform ODP analysis, but under the totality of the Accord Roche retained meaningful rights (secondary suit right, veto on assignments); Accord did not transfer all substantial rights; ODP does not apply. Affirmed. |
| Written description (priority to ’013 application; disclosure of full-length p75 and p75–IgG1 fusion) | Priority application (specification, examples, references to Smith/GenBank and deposited vectors) demonstrates possession of full-length p75 and the claimed p75–IgG1 fusion. | Priority only disclosed a truncated/mutated Figure 4 sequence and broad lists of options without blaze marks to reach the specific full-length p75/I gG1 fusion; thus insufficient written description. | The court: district court’s factual findings are not clearly erroneous—specification and cited prior art would lead a POSA to the full p75 sequence and Example 11 and deposited vectors teach the fusion; written description satisfied. Affirmed. |
| Obviousness (motivation to combine; objective indicia) | A POSA would be deterred from selecting/combining the claimed elements due to concerns (aggregation, inflammation); objective indicia (clinical success, long-felt need, failure of others) have nexus and support nonobviousness. | Prior art and routine design incentives would have motivated a POSA to make the fusion (diagnostic/research utility and routine half-life extensions); the court improperly relied on inventors' subjective aims and misapplied nexus. | The court: no clear error in the district court’s factual findings on motivation to combine (analysis followed the evidence presented) and the presumption of nexus to objective indicia was not rebutted; claims are not obvious. Affirmed. |
Key Cases Cited
- In re Hubbell, 709 F.3d 1140 (Fed. Cir. 2013) (doctrine and purpose of obviousness-type double patenting)
- Eli Lilly & Co. v. Barr Labs., 251 F.3d 955 (Fed. Cir. 2001) (ODP prevents patent term extension by later claims not patentably distinct)
- In re Longi, 759 F.2d 887 (Fed. Cir. 1985) (common-ownership ODP applies even with different inventors/owners over time)
- Alfred E. Mann Found. v. Cochlear Corp., 604 F.3d 1354 (Fed. Cir. 2010) (all-substantial-rights/ownership analysis focuses on enforcement and alienation rights)
- Speedplay, Inc. v. Bebop, Inc., 211 F.3d 1245 (Fed. Cir. 2000) (licensee’s ability to grant royalty-free sublicenses can render licensor’s retained right to sue illusory)
- Lone Star Silicon Innovations LLC v. Nanya Tech. Corp., 925 F.3d 1225 (Fed. Cir. 2019) (totality-of-the-agreement approach for determining effective ownership)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written-description legal standard)
- Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005) (written description need not re-describe known prior art)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (framework for obviousness and motivation to combine)
- WBIP, LLC v. Kohler Co., 829 F.3d 1317 (Fed. Cir. 2016) (presumption of nexus for objective indicia when patentee ties evidence to a product)
- In re Janssen Biotech, 880 F.3d 1315 (Fed. Cir. 2018) (one-way/two-way ODP test and when two-way exception applies)
- In re Basell Poliolefine Italia S.P.A., 547 F.3d 1371 (Fed. Cir. 2008) (PTO responsibility for delay controls two-way test applicability)